POM

GUANGZHOU, China, Oct. 12, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ:POM), a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled healthcare solutions, today highlighted its strategy to participate in the ongoing transformation of healthcare from a traditionally reactive model centered on treating illness after it occurs toward a more predictive and proactive approach to health management.For much of the past century, healthcare delivery has primarily followed an event-driven model in which patients seek medical care after symptoms emerge, physicians diagnose the condition, and treatment follows. While advances in medical

6-K - POMDOCTOR Ltd (0001877971) (Filer)

GUANGZHOU, China, Oct. 9, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ:POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that it received a staff determination letter (the "Letter") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") on October 6, 2026.The Letter notified the Company that the closing bid price of the Company's American depositary shares (the "ADSs") had been below $1.00 per share for 30 consecutive business days, from August 24, 2026 through October 5, 2026. As a result, the Company is not in compliance

6-K - POMDOCTOR Ltd (0001877971) (Filer)

6-K - POMDOCTOR Ltd (0001877971) (Filer)

GUANGZHOU, China, Sept. 30, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ:POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today provided an update on the continued progress in the development and commercialization of its AI-enabled chronic disease management ecosystem, including further optimization of its proprietary AI chronic disease management system, expanded real-world data ("RWD") applications, and integrated in-hospital and out-of-hospital chronic disease management pilots. Pomdoctor has completed multiple rounds of optimization of its AI chronic disease management system, leveraging multidimensional real-world

6-K - POMDOCTOR Ltd (0001877971) (Filer)

6-K - POMDOCTOR Ltd (0001877971) (Filer)

GUANGZHOU, China, Sept. 24, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today highlighted its differentiated "hardware + AI + payment" infrastructure model. The Company believes this integrated approach distinguishes it from traditional internet healthcare platforms and positions Pomdoctor to evolve into a comprehensive digital healthcare technology infrastructure provider. While conventional internet healthcare platforms typically operate in silos, focusing on discrete services such as online consultations, prescription processing or pharmaceutical transactions, Pomdoc

6-K - POMDOCTOR Ltd (0001877971) (Filer)

Virtual company presentation will be available beginning September 11, 2026, at 7:00 a.m. ETGUANGZHOU, China, Sept. 10, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ:POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today announced that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September 14 through September 16, 2026, at the Lotte New York Palace Hotel in New York City. A pre-recorded presentation from the Company as part of the conference will be available on demand beginning Friday, September 11, 2026, at 7:00 a.m. ET. The Company also made available the investor p

6-K - POMDOCTOR Ltd (0001877971) (Filer)

6-K - POMDOCTOR Ltd (0001877971) (Filer)

GUANGZHOU, China, Aug. 27, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ:POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today announced the formal initiation of its U.S. market entry preparations, marking a decisive advancement in its global growth strategy. As part of the initiative, Pomdoctor has recently commenced recruitment for core U.S.-based leadership and operational roles, completed an initial assessment of the U.S. healthcare market, and begun structuring a dedicated local compliance and regulatory framework. Concurrently, the Company is advancing product localization efforts and engaging in exploratory discu

6-K - POMDOCTOR Ltd (0001877971) (Filer)

GUANGZHOU, China, Aug. 10, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its healthcare intelligence flywheel, a closed-loop growth model that integrates AI, wearable devices, healthcare data, professional medical services, and insurance payment networks. The Company believes this model enables each healthcare service cycle to generate incremental data, continuously strengthen AI analytics, enhance service personalization, and boost user engagement. As these capabilities reinforce one another with minimal manual int

6-K - POMDOCTOR Ltd (0001877971) (Filer)

Anchoring Established Healthcare Operations to Technology-Enabled Growth OpportunitiesGUANGZHOU, China, Aug. 3, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ:POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its four-tier diversified revenue structure, which is designed to build on the Company's established healthcare operations while developing scalable, technology-enabled services. The Company's four-tier revenue structure consists of B2C basic healthcare services, AI-enabled chronic disease membership subscriptions, B2B enterprise and hospital services, along wit

S-8 - POMDOCTOR Ltd (0001877971) (Filer)

6-K - POMDOCTOR Ltd (0001877971) (Filer)

6-K - POMDOCTOR Ltd (0001877971) (Filer)

GUANGZHOU, China, July 13, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that on July 10, 2026, the Company received a letter (the "Compliance Letter") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1). As a result, the matter has been closed. As previously disclosed, on January 29, 2026, the Company received a notification letter from Nasdaq indicating that the closing bid pri

6-K - POMDOCTOR Ltd (0001877971) (Filer)

6-K - POMDOCTOR Ltd (0001877971) (Filer)

GUANGZHOU, China, July 2, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced a strategic upgrade, officially positioning the Company as a foundational infrastructure provider for predictive healthcare data and services. The strategic upgrade reflects the Company's continued evolution from a traditional online healthcare platform toward an artificial intelligence ("AI")-enabled healthcare infrastructure provider. By integrating wearable technologies, AI, physician services, real-world healthcare data, and healthcare payment networks, POM aims to develop an intelligent healthcare ecosys